Invivyd Reports Full Year 2022 Financial Results and Business Highlights
March 23, 2023 16:01 ET
|
Invivyd
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term...
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
March 22, 2023 16:30 ET
|
Invivyd
Research published online today in peer-reviewed journal Science Translational MedicineAnalysis of data from a Phase 2/3 COVID-19 prevention study (EVADE) of adintrevimab suggests clinically...
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
March 16, 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies
March 06, 2023 07:00 ET
|
Invivyd
Company seeks to utilize emerging global COVID-19 regulatory frameworks to accelerate development of VYD222 and its pipeline of other candidates VYD222 mAb candidate has demonstrated in vitro...
Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference
February 28, 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory...
Invivyd Announces Changes to Executive Team
February 03, 2023 07:30 ET
|
Invivyd
WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today...
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
December 19, 2022 07:00 ET
|
Invivyd
WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
December 06, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
November 17, 2022 07:00 ET
|
Invivyd
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and...
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022 16:01 ET
|
Invivyd
Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support...